Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-11-19 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于股东钧天创业投资有限公司、重庆渤溢新天股权投资基金合伙企业（有限合伙）减持股份计划公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a planned reduction in shareholding by specific shareholders of Chengdu Lead Drug Development Co., Ltd. It includes information about the shareholders, their shareholding percentages, the planned number of shares to be reduced, the methods of reduction, timing, and regulatory compliance. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not a report of voting results or a management change announcement. It is a formal disclosure about shareholders' intentions to reduce their holdings, which fits the category of Transaction in Own Shares (POS). The document length is about 4788 characters, which is sufficient for a full announcement rather than a brief notice or a report publication announcement. Therefore, the appropriate classification is POS with high confidence.
2024-11-19 Chinese
成都先导药物开发股份有限公司关于召开2024年第三季度业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement about the scheduling of a third-quarter earnings conference call (业绩说明会) for the company 成都先导药物开发股份有限公司. It provides details on the date, time, location, participation method, and contact information for the event. It references the already published third-quarter report but does not contain the financial results or substantive financial data itself. The document is short (1519 characters) and serves as a notice for the upcoming earnings call rather than the call transcript or the quarterly report itself. Therefore, it fits best under the category of Call Transcript (CT) announcement or related. However, since it is only an announcement of the call and not the transcript, and given the options, the closest classification is Call Transcript (CT) as it relates to the earnings call event. Confidence is high due to clear keywords like '业绩说明会' (earnings explanation meeting) and detailed call logistics.
2024-10-31 Chinese
成都先导药物开发股份有限公司2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '成都先导药物开发股份有限公司 2024 年第三季度报告' which translates to 'Chengdu Lead Drug Development Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data for the third quarter of 2024, including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics. The report explicitly states it is unaudited and covers the period from the start of the quarter to the end of the quarter (3 months). The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is over 13,000 characters, so it is not a mere announcement or publication notice. There are no indications that this is an annual report, audit report, or other filing types. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-10-25 Chinese
成都先导药物开发股份有限公司2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 third extraordinary shareholders' meeting of Chengdu Lead Drug Development Co., Ltd. It includes details about the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is short (1663 characters) and it is clearly an announcement of meeting resolutions, not a full report or detailed financial disclosure. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-09-13 Chinese
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2024年第三次临时股东大会的法律意见书
Regulatory Filings
2024-09-13 Chinese
成都先导药物开发股份有限公司关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (567 characters) about the company receiving a government subsidy. It includes details about the subsidy amount, its accounting treatment, and a caution about investment risk. There is no detailed financial data, no full report, and no mention of an attached or forthcoming report. The content is an update on a specific financial event (government subsidy) rather than a full financial report or audit. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-09-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.